MapLight Therapeutics, Inc. Common Stock (MPLT)
Who owns MapLight Therapeutics, Inc. Common Stock (MPLT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 31.4% of the shares are freely tradable; institutional investors hold 56.0%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Novo A/S | 8.13 | 3,686,622 | +0.0 | 03/31/2026 |
| FCPM III SERVICES BV | 7.12 | 3,226,400 | +0.0 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 6.18 | 2,801,937 | -50.0 | 03/31/2026 |
| The Goldman Sachs Group Inc | 4.40 | 1,994,873 | +3.0 | 03/31/2026 |
| BlackRock Inc | 2.95 | 1,339,731 | +22.3 | 03/31/2026 |
| Blue Owl Capital Holdings LP | 2.22 | 1,005,929 | +207.6 | 03/31/2026 |
| Nan Fung Group Holdings Ltd | 2.14 | 971,253 | +0.0 | 03/31/2026 |
| 5AM Venture Management, LLC | 2.10 | 950,011 | +0.0 | 03/31/2026 |
| Sanofi | 2.01 | 912,041 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 1.92 | 869,668 | +0.0 | 12/31/2025 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 30. Jul 2026 | Catalyst4, Inc. | 10% Owner | Buy | 1,000,000 | 13.00 | 13,000,000 |
| 29. Jul 2026 | Catalyst4, Inc. | 10% Owner | Buy | 3,000 | 12.63 | 37,890 |
| 28. Jul 2026 | Catalyst4, Inc. | 10% Owner | Buy | 65,137 | 11.69 | 761,393 |
| 28. Jul 2026 | Catalyst4, Inc. | 10% Owner | Buy | 141,088 | 10.74 | 1,515,511 |
| 28. Jul 2026 | Cox Troy | Director | Buy | 15,620 | 9.52 | 148,702 |
| 17. Jul 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 200 | 38.39 | 7,678 |
| 17. Jul 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 14,140 | 37.70 | 533,078 |
| 17. Jul 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 2,833 | 37.05 | 104,963 |
| 17. Jul 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 900 | 38.17 | 34,353 |
| 17. Jul 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 16,969 | 37.61 | 638,204 |
| 17. Jul 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 600 | 36.51 | 21,906 |
| 17. Jul 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 3,656 | 37.90 | 138,562 |
| 17. Jul 2026 | Hanson Kristopher | General Counsel | Sell | 1,130 | 37.90 | 42,827 |
| 17. Jul 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 2,077 | 37.90 | 78,718 |
| 17. Jul 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 16,779 | 37.90 | 635,924 |
| 16. Jul 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 1,592 | 37.44 | 59,604 |
| 16. Jul 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 7,464 | 36.66 | 273,630 |
| 16. Jul 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 1,476 | 37.44 | 55,261 |
| 16. Jul 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 6,979 | 36.66 | 255,850 |
| 16. Jul 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 19 | 37.96 | 721 |
| 16. Jul 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 5,865 | 37.26 | 218,530 |
| 16. Jul 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 9,163 | 36.46 | 334,083 |
| 16. Jul 2026 | Hanson Kristopher | General Counsel | Sell | 11 | 37.96 | 418 |
| 16. Jul 2026 | Hanson Kristopher | General Counsel | Sell | 3,331 | 37.26 | 124,113 |
| 16. Jul 2026 | Hanson Kristopher | General Counsel | Sell | 4,776 | 36.45 | 174,085 |
| 16. Jul 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 12 | 37.96 | 456 |
| 16. Jul 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 3,526 | 37.26 | 131,379 |
| 16. Jul 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 5,009 | 36.45 | 182,578 |
| 16. Jul 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 92 | 37.96 | 3,492 |
| 16. Jul 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 28,091 | 37.26 | 1,046,671 |
| 16. Jul 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 40,899 | 36.46 | 1,491,178 |
| 15. Jul 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 4,510 | 36.94 | 166,599 |
| 15. Jul 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 5,545 | 36.13 | 200,341 |
| 15. Jul 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 4,699 | 36.94 | 173,581 |
| 15. Jul 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 5,356 | 36.13 | 193,512 |
| 15. Jul 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 18 | 37.54 | 676 |
| 15. Jul 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 8,972 | 36.99 | 331,874 |
| 15. Jul 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 4,465 | 36.00 | 160,740 |
| 15. Jul 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 7,845 | 37.04 | 290,579 |
| 15. Jul 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 7,155 | 36.16 | 258,725 |
| 15. Jul 2026 | Hanson Kristopher | General Counsel | Sell | 10 | 37.54 | 375 |
| 15. Jul 2026 | Hanson Kristopher | General Counsel | Sell | 5,103 | 36.99 | 188,760 |
| 15. Jul 2026 | Hanson Kristopher | General Counsel | Sell | 2,147 | 36.00 | 77,292 |
| 15. Jul 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 12 | 37.54 | 450 |
| 15. Jul 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 5,393 | 36.99 | 199,487 |
| 15. Jul 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 2,238 | 36.00 | 80,568 |
| 15. Jul 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 90 | 37.54 | 3,379 |
| 15. Jul 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 42,738 | 36.99 | 1,580,879 |
| 15. Jul 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 18,950 | 36.00 | 682,200 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.